| Literature DB >> 12951478 |
Noriaki Ohnishi1, Mayako Kusuhara, Mutsunobu Yoshioka, Kazuo Kuroda, Akihiro Soga, Fumi Nishikawa, Tomokazu Koishi, Masato Nakagawa, Satoshi Hori, Tsuyoshi Matsumoto, Masayuki Yamashita, Shunsaku Ohta, Koji Takara, Teruyoshi Yokoyama.
Abstract
The effects of Ginkgo biloba leaf extract (GBE), one of the most widely used herbal dietary supplements in Japan, on the pharmacokinetics of diltiazem (DTZ), a typical probe of cytochrome P450 (CYP) 3A, were examined in rats. The simultaneous addition of GBE to small intestine and liver microsomes inhibited the formation of N-demethyl DTZ (MA), an active metabolite of DTZ produced by CYP3A, in a concentration-dependent manner, with an IC(50) of about 50 and 182 microg/ml, respectively. This inhibition appeared to be caused, at least in part, by a mechanism-based inhibition. Both the rate of formation of MA and total amount of CYP in intestinal or hepatic microsomes after a single oral pretreatment with GBE (20 mg/kg) decreased transiently. The pretreatment significantly decreased the terminal elimination rate constant and increased the mean residence time, after intravenous administration of DTZ (3 mg/kg). Furthermore, it significantly increased the area under the concentration-time curve and absolute bioavailability after oral administration of DTZ (30 mg/kg). These results indicated that the concomitant use of GBE in rats increased the bioavailability of DTZ by inhibiting both intestinal and hepatic metabolism, at least in part, via a mechanism-based inhibition for CYP3A.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12951478 DOI: 10.1248/bpb.26.1315
Source DB: PubMed Journal: Biol Pharm Bull ISSN: 0918-6158 Impact factor: 2.233